dc.contributor.author | Siahmansouri, H | |
dc.contributor.author | Somi, MH | |
dc.contributor.author | Babaloo, Z | |
dc.contributor.author | Baradaran, B | |
dc.contributor.author | Jadidi-Niaragh, F | |
dc.contributor.author | Atyabi, F | |
dc.contributor.author | Mohammadi, H | |
dc.contributor.author | Ahmadi, M | |
dc.contributor.author | Yousefi, M | |
dc.date.accessioned | 2018-08-26T05:37:26Z | |
dc.date.available | 2018-08-26T05:37:26Z | |
dc.date.issued | 2016 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/39859 | |
dc.description.abstract | Over-expressions of HMGA2, vimentin and MMP-9 and downregulation of E-cadherin occur on colorectal cancer cells followed by a reduction in let-7 as a regulatory factor. In this study, we first used carboxymethyl dextran (CMD)-chitosan nanoparticles (ChNPs) platform to encapsulate HMGA2 siRNA and doxorubicin (DOX), and then, we evaluated the efficacy of the simultaneous delivery of siRNA/drug on viability and gene expression of HT-29 cell lines.ChNPs characteristics were determined by a dynamic light scattering and zeta sizer. Morphology of loaded ChNPs was assessed by scanning electron microscopy, and Fourier transform infrared spectroscopy was used to confirm the conjugation of ChNP/siRNA/DOX/CMD. Cell viability and relative mRNA expression were evaluated by MTT assay and real-time PCR, respectively.The prepared ChNPs had high efficiency for siRNA and drug encapsulation (78% and 75%) and were stable against serum and heparin. ChNP/siRNA/DOX/CMD was more effective to induce tumour cell death and also could significantly reduce the expressions of HMGA2, vimentin as well as MMP-9 and increase E-cadherin expression.In conclusion, our results revealed that dual delivery of a key gene siRNA and appropriate anticancer drug have great impact on the treatment of colorectal cancer. | |
dc.language.iso | English | |
dc.relation.ispartof | The Journal of pharmacy and pharmacology | |
dc.subject | Adenocarcinoma | |
dc.subject | Antineoplastic Agents | |
dc.subject | Cadherins | |
dc.subject | Chemistry, Pharmaceutical | |
dc.subject | Chitosan | |
dc.subject | Colorectal Neoplasms | |
dc.subject | Doxorubicin | |
dc.subject | Drug Carriers | |
dc.subject | Drug Combinations | |
dc.subject | Drug Delivery Systems | |
dc.subject | Drug Stability | |
dc.subject | HMGA2 Protein | |
dc.subject | HT29 Cells | |
dc.subject | Humans | |
dc.subject | Matrix Metalloproteinase 9 | |
dc.subject | Nanoparticles | |
dc.subject | Particle Size | |
dc.subject | RNA, Messenger | |
dc.subject | RNA, Small Interfering | |
dc.subject | Vimentin | |
dc.title | Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line. | |
dc.type | article | |
dc.citation.volume | 68 | |
dc.citation.issue | 9 | |
dc.citation.spage | 1119 | |
dc.citation.epage | 30 | |
dc.citation.index | Pubmed | |
dc.identifier.DOI | https://doi.org/10.1111/jphp.12593 | |